A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients

NCT04355117 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.

Sponsor

Otsuka Pharmaceutical Co., Ltd.